Bris­tol My­ers Squibb takes an­oth­er late-stage loss for Op­di­vo-Yer­voy com­bo in head and neck can­cer

Bris­tol My­ers Squibb has worked over­time to hunt down an edge for its PD-(L)1 block­er Op­di­vo over ri­val Keytru­da from Mer­ck, in­clud­ing tak­ing a bold com­bo strat­e­gy with CT­LA4 in­hibitor Yer­voy. But in head and neck can­cer, the com­bo keeps drop­ping duds.

Op­di­vo plus Yer­voy failed to show clin­i­cal ben­e­fit in ex­tend­ing the lives of first-line pa­tients with re­cur­rent or metasta­t­ic squa­mous cell car­ci­no­ma of the head and neck, ac­cord­ing to topline re­sults from the Phase III CHECK­MATE-651 study re­vealed Fri­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER